203 related articles for article (PubMed ID: 38604814)
1. OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS-STING pathway to mediate GBM immune escape.
Zhu W; Rao J; Zhang LH; Xue KM; Li L; Li JJ; Chen QZ; Fu R
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604814
[TBL] [Abstract][Full Text] [Related]
2. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma.
Yi K; Cui X; Liu X; Wang Y; Zhao J; Yang S; Xu C; Yang E; Xiao M; Hong B; Fang C; Kang C; Tan Y; Wang Q
Front Immunol; 2021; 12():802795. PubMed ID: 35069587
[TBL] [Abstract][Full Text] [Related]
3. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
4. Precisely Activating cGAS-STING Pathway with a Novel Peptide-Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy.
Xing Y; Peng A; Yang J; Cheng Z; Yue Y; Liu F; Li F; Liu Y; Liu Q
Adv Sci (Weinh); 2024 Apr; 11(15):e2309583. PubMed ID: 38233164
[TBL] [Abstract][Full Text] [Related]
5. IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion.
Zhao L; Wang Y; Mu P; Zhang X; Qi R; Zhang Y; Zhang H; Zhu X; Dong Z; Dong Y
Cancer Cell Int; 2024 Feb; 24(1):60. PubMed ID: 38326861
[TBL] [Abstract][Full Text] [Related]
6. MiR-10b-5p Impairs TET2-Mediated Inhibition of PD-L1 Transcription Thus Promoting Immune Evasion and Tumor Progression in Glioblastoma.
Du W; Chen D; Wei K; Yu D; Gan Z; Xu G; Yao G
Tohoku J Exp Med; 2023 Jul; 260(3):205-214. PubMed ID: 37019647
[TBL] [Abstract][Full Text] [Related]
7. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
[TBL] [Abstract][Full Text] [Related]
9. The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction.
Himes BT; Peterson TE; de Mooij T; Garcia LMC; Jung MY; Uhm S; Yan D; Tyson J; Jin-Lee HJ; Parney D; Abukhadra Y; Gustafson MP; Dietz AB; Johnson AJ; Dong H; Maus RL; Markovic S; Lucien F; Parney IF
Neuro Oncol; 2020 Jul; 22(7):967-978. PubMed ID: 32080744
[TBL] [Abstract][Full Text] [Related]
10. Phosphofructokinase 1 platelet isoform induces PD-L1 expression to promote glioblastoma immune evasion.
Wang S; Park SH; Lim JS; Park YY; Du L; Lee JH
Genes Genomics; 2022 Dec; 44(12):1509-1517. PubMed ID: 35917090
[TBL] [Abstract][Full Text] [Related]
11. DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients.
Vasiyani H; Mane M; Rana K; Shinde A; Roy M; Singh J; Gohel D; Currim F; Srivastava R; Singh R
Apoptosis; 2022 Dec; 27(11-12):961-978. PubMed ID: 36018392
[TBL] [Abstract][Full Text] [Related]
12. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
13. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
[TBL] [Abstract][Full Text] [Related]
14. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
Shu C; Li Q
Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
[TBL] [Abstract][Full Text] [Related]
15. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
[TBL] [Abstract][Full Text] [Related]
16. Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy.
Lu Q; Chen R; Du S; Chen C; Pan Y; Luan X; Yang J; Zeng F; He B; Han X; Song Y
Biomaterials; 2022 Dec; 291():121871. PubMed ID: 36323073
[TBL] [Abstract][Full Text] [Related]
17. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
[TBL] [Abstract][Full Text] [Related]
18. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
Shida Y; Nakazawa T; Matsuda R; Morimoto T; Nishimura F; Nakamura M; Maeoka R; Yamada S; Nakagawa I; Park YS; Yasukawa M; Tojo T; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576141
[TBL] [Abstract][Full Text] [Related]
19. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer.
Meng J; Peng J; Feng J; Maurer J; Li X; Li Y; Yao S; Chu R; Pan X; Li J; Zhang T; Liu L; Zhang Q; Yuan Z; Bu H; Song K; Kong B
J Transl Med; 2021 Oct; 19(1):415. PubMed ID: 34620163
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.
Yang T; Kong Z; Ma W
Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
